WO2021009487A1 - Compositions d'amélioration du plaisir sexuel - Google Patents

Compositions d'amélioration du plaisir sexuel Download PDF

Info

Publication number
WO2021009487A1
WO2021009487A1 PCT/GB2020/051661 GB2020051661W WO2021009487A1 WO 2021009487 A1 WO2021009487 A1 WO 2021009487A1 GB 2020051661 W GB2020051661 W GB 2020051661W WO 2021009487 A1 WO2021009487 A1 WO 2021009487A1
Authority
WO
WIPO (PCT)
Prior art keywords
sexual pleasure
composition
aliphatic
pleasure enhancement
sexual
Prior art date
Application number
PCT/GB2020/051661
Other languages
English (en)
Inventor
Richard John Mears
Original Assignee
Beauty Dna Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beauty Dna Ltd. filed Critical Beauty Dna Ltd.
Publication of WO2021009487A1 publication Critical patent/WO2021009487A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic

Definitions

  • the present invention relates generally to sexual pleasure enhancement compositions suitable for enhancing sexual pleasure in a subject, wherein the sexual pleasure enhancement compositions comprise at least one aliphatic perfluorocarbon compound.
  • the present invention further relates to the various therapeutic and non-therapeutic uses of these compositions to enhance sexual pleasure in a subject and/or for treating sexual dysfunction in a subject.
  • Sexual pleasure is a complex effect influenced by numerous physical, emotional, and psychological factors. Some subjects experience a recurrent inability to experience or maintain sexual pleasure. Some subjects experience normal sexual pleasure but wish to enhance their sexual pleasure beyond that which they normally experience. It would therefore be beneficial to provide compositions for enhancing sexual pleasure in a subject.
  • a sexual pleasure enhancement composition for enhancing sexual pleasure in a subject, wherein the sexual pleasure enhancement composition comprises at least one aliphatic fluorocarbon compound, wherein at least one aliphatic fluorocarbon compound is an aliphatic perfluorocarbon compound.
  • fluorocarbon compound refers to any compound including carbon and fluorine atoms and including at least one C-F bond.
  • perfluorocarbon compound refers to any hydrocarbon compound that is fully fluorinated. In other words, the compounds contain only carbon and fluorine atoms.
  • the composition further comprises water-swellable microparticles for penetrating the epidermis of a subject.
  • a non- therapeutic method for enhancing sexual pleasure in a subject comprising applying the composition of the first aspect of the present invention to one or more erogenous zones such (particularly the genitals and/or the breasts) of the subject.
  • the sexual pleasure enhancement composition of the first aspect of the present invention for use in a therapeutic method of treating sexual dysfunction in a subject.
  • a therapeutic method for treating sexual dysfunction in a subject comprising applying the sexual pleasure enhancement composition of the first aspect of the present invention to one or more erogenous zones (preferably the genitals and/or the breasts) of the subject.
  • a method for making a sexual pleasure enhancement composition of the first aspect of the present invention comprising mixing the aliphatic fluorocarbon compound(s) with any other components of the sexual pleasure enhancement composition.
  • enhancement of sexual pleasure in a subject e.g. increase in sexual desire, increase in sexual arousal, increased sexual satisfaction, increased sensitivity, deeper orgasm, or more pleasurable orgasm;
  • a sexual pleasure enhancement composition for enhancing sexual pleasure in a subject, wherein the composition comprises at least one aliphatic fluorocarbon compound, wherein at least one aliphatic fluorocarbon compound is an aliphatic perfluorocarbon compound.
  • the sexual pleasure enhancement composition may, for example, comprise from 1 to 10 aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may comprise from 1 to 5 aliphatic fluorocarbon compounds or from 1 to 4 aliphatic fluorocarbon compounds or from 1 to 3 aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example, comprise at least 2 aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example comprise from 2 to 10 aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may comprise from 2 to 5 aliphatic fluorocarbon compounds or from 2 to 4 aliphatic fluorocarbon compounds or from 2 to 3 aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example comprise at least 3 aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example comprise from 3 to 10 aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may comprise from 3 to 5 aliphatic fluorocarbon compounds or from 3 to 4 aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example, comprise 1 , 2, or 3 aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may comprise 3 aliphatic fluorocarbon compounds.
  • At least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may, for example, comprise from 1 to 20 carbon atoms.
  • at least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may comprise from 2 to 20 carbon atoms or from 3 to 20 carbon atoms or from 4 to 20 carbon atoms or from 5 to 20 carbon atoms or from 8 to 20 carbon atoms.
  • at least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may comprise from 1 to 15 carbon atoms or from 2 to 15 carbon atoms or from 3 to 15 carbon atoms or from 4 to 15 carbon atoms or from 5 to 15 carbon atoms or from 8 to 15 carbon atoms.
  • All of the aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition described herein may, for example, comprise from 1 to 20 carbon atoms.
  • all of the aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition described herein may comprise from 2 to 20 carbon atoms or from 3 to 20 carbon atoms.
  • all of the aliphatic fluorocarbon compound(s) present in the composition described herein may comprise from 1 to 15 carbon atoms or from 2 to 15 carbon atoms or from 3 to 15 carbon atoms.
  • Aliphatic fluorocarbon compounds may, for example, comprise other atoms including, for example, one or more of hydrogen, nitrogen, oxygen, sulphur, phosphorus, chlorine, bromine, and iodine.
  • At least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may consist of (i.e. include only) carbon atoms, fluorine atoms, and optionally hydrogen atoms.
  • the sexual pleasure enhancement composition may, for example, comprise from 1 to 10 aliphatic fluorocarbon compounds consisting of carbon atoms, fluorine atoms, and optionally hydrogen atoms.
  • the sexual pleasure enhancement composition may comprise from 1 to 5 or from 1 to 4 or from 1 to 3 aliphatic fluorocarbon compounds consisting of carbon atoms, fluorine atoms, and optionally hydrogen atoms.
  • the sexual pleasure enhancement composition may, for example, comprise from 2 to 10 aliphatic fluorocarbon compounds consisting of carbon atoms, fluorine atoms, and optionally hydrogen atoms.
  • the sexual pleasure enhancement composition may comprise from 2 to 5 or from 2 to 4 or from 2 to 3 aliphatic fluorocarbon compounds consisting of carbon atoms, fluorine atoms, and optionally hydrogen atoms.
  • the sexual pleasure enhancement composition may, for example, comprise from 3 to 10 aliphatic fluorocarbon compounds consisting of carbon atoms, fluorine atoms, and optionally hydrogen atoms.
  • the sexual pleasure enhancement composition may comprise from 3 to 5 or from 3 to 4 aliphatic fluorocarbon compounds consisting of carbon atoms, fluorine atoms, and optionally hydrogen atoms.
  • All of the aliphatic fluorocarbon compound(s) present in the composition described herein may, for example, consist of (i.e. include only) carbon atoms, fluorine atoms, and optionally hydrogen atoms.
  • the total number of aliphatic fluorocarbon compound(s) present in the composition may be from 1 to 10 or from 1 to 5 or from 1 to 4 or from 1 to 3.
  • the total number of aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition in this embodiment may be 1 , 2, or 3.
  • At least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may consist of carbon atoms, fluorine atoms, and hydrogen atoms (i.e. include all 3 of carbon atoms, fluorine atoms, and hydrogen atoms).
  • An example of an aliphatic fluorocarbon compound consisting of carbon atoms, fluorine atoms, and hydrogen atoms is pentafluoropropane.
  • the sexual pleasure enhancement composition may, for example, comprise from 1 to 10 aliphatic fluorocarbon compounds consisting of carbon atoms, fluorine atoms, and hydrogen atoms (i.e. including all 3 of carbon atoms, fluorine atoms, and hydrogen atoms).
  • the sexual pleasure enhancement composition may comprise from 1 to 5 or from 1 to 4 or from 1 to 3 aliphatic fluorocarbon compounds consisting of carbon atoms, fluorine atoms, and hydrogen atoms (i.e. including all 3 of carbon atoms, fluorine atoms, and hydrogen atoms).
  • the sexual pleasure enhancement composition may comprise 1 aliphatic fluorocarbon compound consisting of carbon atoms, fluorine atoms, and hydrogen atoms (i.e. including all 3 of carbon atoms, fluorine atoms, and hydrogen atoms).
  • At least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein consists of (i.e. includes only) carbon atoms and fluorine atoms.
  • the sexual pleasure enhancement composition includes at least one aliphatic perfluorocarbon compound.
  • aliphatic perfluorocarbon compounds consisting of carbon atoms and fluorine atoms include perfluorohexane and perfluorodecalin.
  • the sexual pleasure enhancement composition may, for example, comprise from 1 to 10 aliphatic perfluorocarbon compounds.
  • the sexual pleasure enhancement composition may comprise from 1 to 5 or from 1 to 4 or from 1 to 3 aliphatic perfluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example, comprise at least 2 aliphatic perfluorocarbon compounds.
  • the sexual pleasure enhancement composition may comprise from 2 to 10 or from 2 to 5 or from 2 to 4 or from 2 to 3 aliphatic perfluorocarbon compounds.
  • the sexual pleasure enhancement composition may comprise 2 aliphatic perfluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example, comprise at least one aliphatic fluorocarbon compound consisting of carbon atoms, fluorine atoms, and hydrogen atoms and at least one aliphatic perfluorocarbon compound.
  • the sexual pleasure enhancement composition may, for example, comprise from 1 to 5 aliphatic fluorocarbon compound(s) consisting of carbon atoms, fluorine atoms, and hydrogen atoms (i.e. including all 3 of carbon atoms, fluorine atoms, and hydrogen atoms) and from 1 to 5 aliphatic perfluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example, comprise 1 aliphatic fluorocarbon compound consisting of carbon atoms, fluorine atoms, and hydrogen atoms and 2 aliphatic perfluorocarbon compounds.
  • Aliphatic fluorocarbon compounds may, for example, be saturated (e.g. fluoroalkane compounds) or unsaturated (e.g. fluoroalkene compounds, fluoroalkyne compounds).
  • At least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may, for example, be a saturated aliphatic fluorocarbon compound.
  • the sexual pleasure enhancement composition may, for example, comprise from 1 to 10 saturated aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may comprise from 1 to 5 or from 1 to 4 or from 1 to 3 saturated aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example, comprise at least 2 saturated aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may comprise from 2 to 10 or from 2 to 5 or from 2 to 4 or from 2 to 3 saturated aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may, for example, comprise at least 3 saturated aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement composition may comprise from 3 to 10 or from 3 to 5 or from 3 to 4 saturated aliphatic fluorocarbon compounds.
  • At least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may, for example, be a fluoroalkane compound.
  • fluoroalkane compounds refers to a saturated hydrocarbon compound in which one or more of the C-H bonds has been replaced by a C-F bond.
  • the fluoroalkane compounds may be linear or cyclic.
  • the sexual pleasure enhancement composition may, for example, comprise from 1 to 10 fluoroalkane compound(s).
  • the sexual pleasure enhancement composition may comprise from 1 to 5 or from 1 to 4 or from 1 to 3 fluoroalkane compounds.
  • the sexual pleasure enhancement composition may, for example, comprise at least 2 fluoroalkane compounds.
  • the composition may comprise from 2 to 10 or from 2 to 5 or from 2 to 4 or from 2 to 3 fluoroalkane compounds.
  • the sexual pleasure enhancement composition may, for example, comprise at least 3 fluoroalkane compounds.
  • the sexual pleasure enhancement composition may comprise from 3 to 10 or from 3 to 5 or from 3 to 4 fluoroalkane compounds.
  • All of the aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition described herein may, for example, be saturated aliphatic fluorocarbon compounds.
  • the total number of aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition may be from 1 to 10 or from 1 to 5 or from 1 to 4 or from 1 to 3.
  • the total number of aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition in this embodiment may be 1 , 2, or 3.
  • All of the aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition described herein may, for example, be fluoroalkane compounds.
  • the total number of aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition may be from 1 to 10 or from 1 to 5 or from 1 to 4 or from 1 to 3.
  • the total number of aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition in this embodiment may be 1 , 2, or 3.
  • Aliphatic fluorocarbon compounds may, for example, be linear or cyclic.
  • the sexual pleasure enhancement compositions described herein may, for example, comprise at least one cyclic aliphatic fluorocarbon compound.
  • the sexual pleasure enhancement compositions described herein may, for example, comprise from 1 to 10 cyclic aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement compositions described herein may comprise from 1 to 5 or from
  • the sexual pleasure enhancement compositions described herein may comprise 1 cyclic aliphatic fluorocarbon compound.
  • a cyclic aliphatic fluorocarbon compound include perfluorodecalin, perfluorodimethylcyclohexane, and perfluoroperhydrophenanthrene.
  • the sexual pleasure enhancement compositions described herein may, for example, comprise at least one linear aliphatic fluorocarbon compound.
  • the sexual pleasure enhancement compositions described herein may comprise from 1 to 10 or from 1 to 5 or from 1 to 4 or from 1 to 3 or from 1 to 2 linear aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise at least 2 linear aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement compositions described herein may comprise from 2 to 10 or from 2 to 5 or from 2 to 4 or from 2 to 3 linear aliphatic fluorocarbon compounds.
  • the sexual pleasure enhancement compositions described herein may comprise 1 or 2 linear aliphatic fluorocarbon compounds. Examples of linear fluorocarbon compounds include pentafluoropropane and perfluorhexane.
  • the sexual pleasure enhancement compositions described herein may comprise at least one linear aliphatic fluorocarbon compound and at least one cyclic aliphatic fluorocarbon compound.
  • the sexual pleasure enhancement compositions described herein may comprise at least 2 linear aliphatic fluorocarbon compounds and at least one cyclic aliphatic fluorocarbon compound.
  • the sexual pleasure enhancement compositions described herein may comprise 2 linear aliphatic fluorocarbon compounds and one cyclic aliphatic fluorocarbon compound.
  • the sexual pleasure enhancement compositions described herein may, for example, comprise at least one saturated aliphatic perfluorocarbon compound.
  • the saturated aliphatic perfluorocarbon compound(s) may, for example, be aliphatic perfluoroalkane compounds.
  • the sexual pleasure enhancement compositions described herein may comprise from 1 to 10 or from 1 to 5 or from 1 to 4 or from 1 to 3 or from 1 to
  • the sexual pleasure enhancement compositions described herein may comprise from 1 to 10 or from 1 to 5 or from 1 to 4 or from 1 to 3 or from 1 to 2 aliphatic perfluoroalkane compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise at least 2 saturated aliphatic perfluorocarbon compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise at least 2 aliphatic peril uoroalkane compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise from 2 to 10 or from 2 to 5 or from 2 to 4 or from 2 to 3 saturated aliphatic perfluorocarbon compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise from 2 to 10 or from 2 to 5 or from 2 to 4 or from 2 to 3 aliphatic perfluoroalkane compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise 1 or 2 saturated aliphatic perfluorocarbon compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise 1 or 2 aliphatic perfluoroalkane compound(s).
  • saturated aliphatic perfluorocarbon compounds include perfluorodecalin and peril uorohexane.
  • the sexual pleasure enhancement compositions described herein may, for example, comprise at least one cyclic aliphatic perfluorocarbon compound.
  • the sexual pleasure enhancement compositions described herein may comprise from 1 to 10 or from 1 to 5 or from 1 to 4 or from 1 to 3 or from 1 to 2 cyclic aliphatic perfluorocarbon compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise at least 2 cyclic aliphatic perfluorocarbon compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise from 2 to 10 or from 2 to 5 or from 2 to 4 or from 2 to 3 cyclic aliphatic perfluorocarbon compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise 1 cyclic aliphatic perfluorocarbon compound(s).
  • An examples of a cyclic aliphatic perfluorocarbon compound is perfluorodecalin.
  • the sexual pleasure enhancement compositions described herein may, for example, comprise at least one cyclic aliphatic perfluoroalkane compound.
  • the sexual pleasure enhancement compositions described herein may comprise from 1 to 10 or from 1 to 5 or from 1 to 4 or from 1 to 3 or from 1 to 2 cyclic aliphatic perfluoroalkane compound(s).
  • the sexual pleasure enhancement compositions described herein may comprise 1 cyclic aliphatic perfluoroalkane compound(s).
  • An example of a cyclic aliphatic perfluoroalkane compound is perfluorodecalin.
  • the sexual pleasure enhancement compositions described herein may, for example, comprise at least one cyclic aliphatic perfluoroalkane compound, at least one linear aliphatic perfluoroalkane compound, and at least one linear aliphatic fluoroalkane compound consisting of carbon, fluorine, and hydrogen atoms.
  • the sexual pleasure enhancement compositions described herein may comprise one cyclic aliphatic perfluoroalkane compound, one linear aliphatic perfluoroalkane compound, and one linear aliphatic fluoroalkane compound consisting of carbon, fluorine, and hydrogen atoms.
  • At least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may, for example, be selected from the group consisting of pentafluoropropane, perfluorodecalin, perfluorohexane, perfluorodimethylcyclohexane, and perfluoroperhydrophenanthrene.
  • Pentafluoropropane has the chemical formula C 3 H 3 F 5 and the structure shown below.
  • Perfluorodecalin has the chemical formula C 10 F 18 and the structure shown below.
  • Perfluorohexane has the chemical formula C 6 FM and the structure shown below.
  • Perfluorodimethylcyclohexane has the chemical formula CsFi 6 and the structure shown below.
  • Perfluoroperhydrophenanthrene has the chemical formula C14F24 and the structure shown below.
  • the sexual pleasure enhancement composition may, for example, comprise from 1 to 5 or from 1 to 4 or from 1 to 3 aliphatic fluorocarbon compounds selected from the group consisting of pentafluoropropane, perfluorodecalin, perfluorohexane, perfluorodimethylcyclohexane, and perfluoroperhydrophenanthrene.
  • the sexual pleasure enhancement composition may, for example, comprise at least 2 aliphatic fluorocarbon compounds selected from the group consisting of pentafluoropropane, perfluorodecalin, perfluorohexane, perfluorodimethylcyclohexane, and perfluoroperhydrophenanthrene.
  • the sexual pleasure enhancement composition may comprise from 2 to 5 or from 2 to 4 or 2, 3, or 4 aliphatic fluorocarbon compounds selected from the group consisting of pentafluoropropane, perfluorodecalin, perfluorohexane, perfluorodimethylcyclohexane, and perfluoroperhydrophenanthrene.
  • the sexual pleasure enhancement composition may, for example, comprise at least 3 aliphatic fluorocarbon compounds selected from the group consisting of pentafluoropropane, perfluorodecalin, perfluorohexane, perfluorodimethylcyclohexane, and perfluoroperhydrophenanthrene.
  • the composition may comprise from 3 to 5 or from 3 to 4 aliphatic fluorocarbon compounds selected from the group consisting of pentafluoropropane, perfluorodecalin, perfluorohexane, perfluorodimethylcyclohexane, and perfluoroperhydrophenanthrene.
  • all of the aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition may be selected from the group consisting of pentafluoropropane, perfluorodecalin, perfluorohexane, perfluorodimethylcyclohexane, and perfluoroperhydrophenanthrene.
  • the total number of aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition may be from 1 to 5 or from 1 to 4 or from 1 to 3.
  • the total number of aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition in this embodiment may be 1 , 2, 3, or 4.
  • At least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may, for example, be selected from the group consisting of pentafluoropropane, perfluorodecalin, and perfluorohexane.
  • the sexual pleasure enhancement composition may, for example, comprise aliphatic fluorocarbon compounds selected from the group consisting of pentafluoropropane, perfluorodecalin, perfluorohexane, and mixtures thereof.
  • the sexual pleasure enhancement composition may, for example, comprise at least 2 aliphatic fluorocarbon compounds selected from the group consisting of pentafluoropropane, peril uorodecalin, and perfluorohexane.
  • all of the aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition may be selected from the group consisting of pentafluoropropane, perfluorodecalin, and perfluorohexane.
  • the total number of aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition may be from 1 to 3.
  • the total number of aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition in this embodiment may be 1 , 2, or 3.
  • the sexual pleasure enhancement composition may, for example, comprise pentafluoropropane, perfluorodecalin, and perfluorohexane.
  • the sexual pleasure enhancement composition may comprise pentafluoropropane, perfluorodecalin, and perfluorohexane as the only aliphatic fluorocarbon compounds in the sexual pleasure enhancement composition.
  • At least one aliphatic fluorocarbon compound present in the sexual pleasure enhancement composition described herein may be liquid or gel at room temperature (about 20°C).
  • all of the aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition described herein may be liquid or gel at room temperature (about 20°C).
  • All of the components of the composition described herein may, for example, be liquid or gel at room temperature (about 20°C).
  • the liquid may, for example, be a suspension or an emulsion.
  • the sexual pleasure enhancement composition may contain any amount of aliphatic fluorocarbon compound(s) effective to enhance sexual pleasure in a subject.
  • the sexual pleasure enhancement composition may, for example, comprise equal to or greater than about 0.01 wt% total aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may comprise equal to or greater than about 0.05 wt% or equal to or greater than about 0.1 wt% or equal to or greater than about 0.5 wt% or equal to or greater than about 1.0 wt% or equal to or greater than about 1.5 wt% or equal to or greater than about 2.0 wt% or equal to or greater than about 2.5 wt% or equal to or greater than about 3.0 wt% or equal to or greater than about 3.5 wt% or equal to or greater than about 4.0 wt% or equal to or greater than about 4.5 wt% or equal to or greater than about 5.0 wt% total aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may, for example, comprise equal to or less than about 10.0 wt% total aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may comprise equal to or less than about 9.5 wt% or equal to or less than about 9.0 wt% equal to or less than about 8.5 wt% equal to or less than about 8.0 wt% or equal to or less than about 7.5 wt% total aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may comprise from about 0.01 wt% to about 10.0 wt% or from about 0.05 wt% to about 9.5 wt% or from about 0.1 wt% to about 9.0 wt% or from about 0.5 wt% to about 8.5 wt% or from about 1.0 wt% to about 8.0 wt% total aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may, for example, comprise equal to or greater than about 0.01 wt% perfluorohexane.
  • the composition may comprise equal to or greater than about 0.05 wt% or equal to or greater than about 0.1 wt% or equal to or greater than about 0.5 wt% or equal to or greater than about 1.0 wt% or equal to or greater than about 1.5 wt% or equal to or greater than about 2.0 wt% or equal to or greater than about 2.5 wt% or equal to or greater than about 3.0 wt% or equal to or greater than about 3.5 wt% perfluorohexane.
  • the sexual pleasure enhancement composition may, for example, comprise equal to or less than about 10.0 wt% perfluorohexane.
  • the composition may comprise equal to or less than about 9.0 wt% or equal to or less than about 8.0 wt% or equal to or less than about 7.0 wt% or equal to or less than about 6.0 wt% or equal to or less than about 5.0 wt% or equal to or less than about 4.5 wt% or equal to or less than about 4.0 wt% perfluorohexane.
  • the sexual pleasure enhancement composition may comprise from about 0.01 wt% to about 10.0 wt% or from about 0.05 wt% to about 8.0 wt% or from about 0.1 wt% to about 6.0 wt% or from about 0.5 wt% to about 5.0 wt% or from about 1.0 wt% to about 4.0 wt% or from about 1.5 wt% to about 4.0 wt% or from about 2.0 wt% to about 4.0 wt% perfluorohexane.
  • the sexual pleasure enhancement composition may, for example, comprise equal to or greater than about 0.01 wt% perfluorodecalin.
  • the composition may comprise equal to or greater than about 0.05 wt% or equal to or greater than about 0.1 wt% or equal to or greater than about 0.5 wt% perfluorodecalin.
  • the sexual pleasure enhancement composition may, for example, comprise equal to or less than about 5.0 wt% perfluorodecalin.
  • the composition may comprise equal to or less than about 4.5 wt% or equal to or less than about 4.0 wt% equal to or less than about 3.5 wt% equal to or less than about 3.0 wt% or equal to or less than about 2.5 wt% or equal to or less than about 2.0 wt% or equal to or less than about 1.5 wt% or equal to or less than about 1.0 wt% perfluorodecalin.
  • the sexual pleasure enhancement composition may comprise from about 0.01 wt% to about 5.0 wt% or from about 0.05 wt% to about 3.0 wt% or from about 0.1 wt% to about 2.0 wt% or from about 0.1 wt% to about 1.0 wt% perfluorodecalin.
  • the sexual pleasure enhancement composition may, for example, comprise equal to or greater than about 0.01 wt% pentafluoropropane.
  • the composition may comprise equal to or greater than about 0.05 wt% or equal to or greater than about 0.1 wt% or equal to or greater than about 0.5 wt% pentafluoropropane.
  • the sexual pleasure enhancement composition may, for example, comprise equal to or less than about 5.0 wt% pentafluoropropane.
  • the composition may comprise equal to or less than about 4.5 wt% or equal to or less than about 4.0 wt% equal to or less than about 3.5 wt% equal to or less than about 3.0 wt% or equal to or less than about 2.5 wt% or equal to or less than about 2.0 wt% or equal to or less than about 1.0 wt% pentafluoropropane.
  • the sexual pleasure enhancement composition may comprise from about 0.01 wt% to about 5.0 wt% or from about 0.05 wt% to about 3.0 wt% or from about 0.1 wt% to about 2.0 wt% or from about 0.1 wt% to about 1.0 wt% pentafluoropropane.
  • the sexual pleasure enhancement composition may, for example, comprise:
  • the sexual pleasure enhancement composition may, for example, comprise:
  • the sexual pleasure enhancement composition may, for example, comprise:
  • the aliphatic perfluorocarbon compound(s) present in the sexual pleasure enhancement composition enable the composition to solubilize oxygen and thus increase delivery of oxygen to the area of skin to which the sexual pleasure enhancement composition is applied.
  • the aliphatic perfluorocarbon compound(s) present in composition penetrate through the layers of the skin, thus increasing delivery of oxygen to that area of the skin. This may stimulate blood flow, thereby increasing sensitivity.
  • the aliphatic perfluorocarbon compound(s) provide an instant refreshing effect to the skin due to its emollient character creating a thin film application.
  • the aliphatic perfluorocarbon compound(s) present in the sexual pleasure enhancement composition may enable the sexual pleasure enhancement composition to carry gases present in the air.
  • the sexual pleasure enhancement compositions can be enriched with oxygen, for example by bubbling medical grade oxygen through the fluorocarbon materials or through the sexual pleasure composition.
  • the sexual pleasure enhancement composition will need to be kept in special air tight packaging to prevent diffusion of the oxygen from the sexual pleasure enhancement composition.
  • the aliphatic fluorocarbon compounds may hold oxygen within their structures, thus increasing delivery of oxygen to the skin of the subject, thereby further enhancing sexual pleasure.
  • At least about 0.1 vol% of the gas dissolved in the fluorocarbon compound(s) may comprise oxygen. In certain embodiments, at least about 5.0 vol% or at least about 10.0 vol% or at least about 15.0 vol% or at least about 20.0 vol% of the gas dissolved in the fluorocarbon compound(s) may comprise oxygen. In certain embodiments, the gas dissolved in the fluorocarbon compound(s) is air and thus contains about 20.0 - 21.0 vol% oxygen.
  • the aliphatic fluorocarbon compound(s) present in the sexual pleasure enhancement composition may be pre-loaded with oxygen before they are incorporated into the sexual pleasure enhancement composition.
  • the gas dissolved in the fluorocarbon compound(s) may comprise at least about 20.0 vol% or at least about 30.0 vol% or at least about 40.0 vol% or at least about 50.0 vol% or at least about 60.0 vol% or at least about 70.0 vol% or at least about 80.0 vol% oxygen.
  • the gas dissolved in the fluorocarbon compound(s) may comprise up to about 100.0 vol% or up to about 99.0 vol% or up to about 98.0 vol% or up to about 95.0 vol% or up to about 90.0 vol% oxygen.
  • the gas dissolved in the fluorocarbon compound(s) may comprise from about 20.0 vol% to about 100.0 vol% or from about 40.0 vol% to about 100.0 vol% or from about 50.0 to about 99.0 vol% or from about 60.0 vol% to about 98.0 vol% oxygen.
  • 1000 ml of the fluorocarbon compounds may contain about 460 ml of air. Since air contains about 20 vol% oxygen, 1000 ml of the fluorocarbon compounds contain about 92 ml of oxygen.
  • the fluorocarbon compounds could then be enriched such that about 40 vol% of the dissolved gas is oxygen (about 184 ml) or about 60 vol% of the dissolved gas is oxygen (about 276 ml) or about 80 vol% of the dissolved gas is oxygen (about 368 ml).
  • This can be measured using an oxygen meter.
  • the dissolved oxygen can be measured using a sensor with a membrane covering the polarimetric sensor and a temperature sensor. The membrane isolates the sensor (platinum cathode) from the test solution and allows the entry of dissolved oxygen. When a voltage is applied to the sensor, oxygen creates an electrical current proportional to the dissolved oxygen concentration.
  • the same method could be used to determine the proportion of oxygen in the dissolved gas in the sexual pleasure composition as a whole.
  • the gas dissolved in the sexual pleasure enhancement composition may comprise at least about 0.1 vol% oxygen.
  • the gas dissolved in the sexual pleasure enhancement composition may comprise at least about 10.0 vol% or at least about 20.0 vol% or at least about 30.0 vol% or at least about 40.0 vol% or at least about 50.0 vol% or at least about 60.0 vol% or at least about 70.0 vol% or at least about 80.0 vol% oxygen.
  • the gas dissolved in the sexual pleasure enhancement composition may comprise up to about 100.0 vol% or up to about 99.0 vol% or up to about 98.0 vol% or up to about 95.0 vol% or up to about 90.0 vol% oxygen.
  • the gas dissolved in the sexual pleasure enhancement composition may comprise from about 0.1 vol% to about 100.0 vol% or from about 20.0 vol% to about 100.0 vol% or from about 40.0 vol% to about 100.0 vol% or from about 50.0 vol% to about 99.0 vol% or from about 60.0 vol% to about 98.0 vol% oxygen.
  • compositions of the present invention further include water-swellable microparticles suitable for or capable of penetrating the epidermis of a subject.
  • Microparticles typically have a size between 1 pm and 1000 pm.
  • the water-swellable microparticles have a particle size of 100 pm or less. In general, smaller microparticles will more easily penetrate the epidermis of the subject.
  • Water-swellable means that the microparticles absorb water and/or forms a gel or gum when immersed in water. Without wishing to be bound by theory, it is believed that the water-swellable microparticles that penetrate the epidermis of a subject may absorb water from, for example, the deep dermis. The water-swellable microparticles may typically expand or swell after absorbing water. The expansion or swelling of the microparticles may heighten sensitivity of the surrounding tissue.
  • the composition includes water-swellable microparticles having a particle size in the range of 1 pm to 50 pm. In particular embodiments, the composition includes water-swellable microparticles having a particle size in the range of 1 pm to 20 pm. In more particular embodiments, the composition includes water-swellable microparticles having a particle size in the range of 3 pm to 20 pm.
  • the particle size of individual particle may be measured, for example, using electron scanning microscopy or confocal microscopy.
  • At least 10 % by number of the water-swellable microparticles in the composition have a particle size in the range of 1 pm to 50 pm. In particular embodiments, at least 10 % by number of the water-swellable microparticles in the composition have a particle size in the range of 1 pm to 20 pm. In further embodiments, at least 10 % by number of the water-swellable microparticles in the composition have a particle size in the range of 3 pm to 20 pm.
  • At least 25 % by number of the water-swellable microparticles in the composition have a particle size in the range of 1 pm to 50 pm. In particular embodiments, at least 25 % by number of the water-swellable microparticles in the composition have a particle size in the range of 1 pm to 20 pm. In further embodiments, at least 25 % by number of the water-swellable microparticles in the composition have a particle size in the range of 3 pm to 20 pm.
  • At least 50 % by number of the water-swellable microparticles in the composition have a particle size in the range of 1 pm to 50 pm. In particular embodiments, at least 50 % by number of the water-swellable microparticles in the composition have a particle size in the range of 1 pm to 20 pm. In further embodiments, at least 50 % by number of the water-swellable microparticles in the composition have a particle size in the range of 3 pm to 20 pm. In some embodiments, at least 75 % by number of the water-swellable microparticles in the composition have a particle size in the range of 1 pm to 50 pm.
  • At least 75 % by number of the water-swellable microparticles in the composition have a particle size in the range of 1 pm to 20 pm. In further embodiments, at least 75 % by number of the water-swellable microparticles in the composition have a particle size in the range of 3 pm to 20 pm.
  • the composition includes water-swellable microparticles that are swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm.
  • the composition may include water-swellable particles swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm to 100 pm, of greater than 20 pm to 80 pm, or of greater than 20 pm to 60 pm.
  • At least 10 % by number of the water-swellable microparticles in the composition are swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm. In certain embodiments, at least 10 % by number of the water- swellable microparticles in the composition are swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm to 100 pm, of greater than 20 pm to 80 pm, or of greater than 20 pm to 60 pm.
  • At least 25 % by number of the water-swellable microparticles in the composition are swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm. In certain embodiments, at least 25 % by number of the water- swellable microparticles in the composition are swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm to 100 pm, of greater than 20 pm to 80 pm, or of greater than 20 pm to 60 pm.
  • At least 50 % by number of the water-swellable microparticles in the composition are swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm. In certain embodiments, at least 50 % by number of the water- swellable microparticles in the composition are swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm to 100 pm, of greater than 20 pm to 80 pm, or of greater than 20 pm to 60 pm. In some embodiments, at least 75 % by number of the water-swellable microparticles in the composition are swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm.
  • At least 75 % by number of the water- swellable microparticles in the composition are swellable from a particle size of 1 pm to 20 pm to a particle size of greater than 20 pm to 100 pm, of greater than 20 pm to 80 pm, or of greater than 20 pm to 60 pm.
  • the water-swellable microparticles include water-swellable biopolymers.
  • water-swellable biopolymers include water-swellable proteins, and water-swellable oligo- and poly-saccharides.
  • the water-swellable microparticles include one or more water-swellable oligo- or poly-saccharides.
  • polysaccharide microparticles suitable for the present invention are those described in US 5,562,924, the contents of which is incorporated herein in its entirety.
  • Specific examples of polysaccharides that may be included in the water-swellable microparticles include hyaluronic acid (and salts thereof), galactomannans, carrageenans, glucomannans, natural gums, pectin, amylose and amylopectin.
  • the water-swellable microparticles include a hygroscopic material.
  • the hygroscopic material may be a hygroscopic biopolymer, such as a hygroscopic polysaccharide.
  • hygroscopic polysaccharides include hyaluronic acid (or salts thereof) and glucomannans.
  • the water-swellable microparticles include two or more water-swellable (e.g. hygroscopic) materials.
  • the two or more water-swellable (e.g. hygroscopic) materials may be cross-linked to each other.
  • the water-soluble microparticles comprise hyaluronic acid cross-linked with a second polysaccharide or sodium hyaluronate cross-linked with a second polysaccharide.
  • the second polysaccharide may be a hygroscopic polysaccharide.
  • the second polysaccharide may be a glucomannan, such as glucomannans derived from konjac ( Amorphophallus konjac).
  • the water-swellable microparticles include hyaluronic acid or a salt thereof.
  • the water-swellable microparticles include sodium hyaluronate.
  • Examples of water-swellable microparticles including hyaluronic acid or a salt thereof include but are not limited to Hyaluronic Filling SpheresTM and Ultra Filling SpheresTM, both available from the Beauty Creations range from BASF®.
  • the composition may comprise water-swellable microcapsules in the range of 0.001 to 0.5 wt. % based on the total weight of the composition. In some embodiments, the composition comprises water-swellable microcapsules in the range of 0.005 to 0.1 wt. % based on the total weight of the composition. In further embodiments, the composition comprises water-swellable microcapsules in the range of 0.005 to 0.05 wt. % based on the total weight of the composition.
  • the sexual pleasure enhancement compositions may, for example, further comprise one or more additional components.
  • additional components that may be present in the sexual pleasure enhancement compositions described herein may, for example, be found in Remington: The Science and Practice of Pharmacy, Mack Publishing Company, 19 th Edition (1995), the contents of which are incorporated herein by reference.
  • the sexual pleasure enhancement compositions may further comprise one or more further ingredients selected from diluents, solvents, preservatives, humectants, emollients, moisturizing agents, buffers, viscosity controlling agents, emulsifiers, gelling agents, demulcents, anti-oxidants, solubilizing agents, skin-penetration agents, surfactants, suspending agents, fragrances, colouring agents, and flavouring agents.
  • further ingredients selected from diluents, solvents, preservatives, humectants, emollients, moisturizing agents, buffers, viscosity controlling agents, emulsifiers, gelling agents, demulcents, anti-oxidants, solubilizing agents, skin-penetration agents, surfactants, suspending agents, fragrances, colouring agents, and flavouring agents.
  • the sexual pleasure enhancement compositions may further comprise one or more further ingredients selected from diluents, solvents, preservatives, humectants, emollients, moisturizing agents, buffering agents, viscosity controlling agents, skin conditioning agents, and emulsifiers.
  • Certain compounds may have more than one effect, e.g. may act as both a diluent and a surfactant, and therefore fall within more than one class of additional component.
  • diluents include, for example, water (e.g. purified water), glycerine, isotonic sodium chloride, and ethanol.
  • solvents include, for example, water, polyalcohol, denatured alcohol, and pentylene glycol.
  • preservatives include, for example, quaternary ammonium compounds, such as dehydroacetic acid, benzalkonium chloride, benzethonium chloride, cetrimide, dequalinium chloride, and cetylpyridinium chloride; mercurial agents, such as phenylmercuric nitrate, phenylmercuric acetate, and thimerosal; alcoholic agents, for example, chlorobutanol, phenylethyl alcohol, and benzyl alcohol; parabens such as methyl paraben, ethylparaben, propylparaben, and butylparaben; antibacterial esters, for example, esters of parahydroxybenzoic acid; and other anti-microbial agents such as chlorhexidine, chlorocresol, benzoic acid, polymyxin, and phenoxyethanol.
  • the preferred preservatives are dehydroacetic acid and benzyl alcohol.
  • humectants include, for example, butylene glycol, propylene glycol, hexylene glycol, glycerin, aloe vera gel, alpha hydroxyl acids, glyceryl triacetate, polymeric polyols, and sugar alcohols such as glycerol, sorbitol, xylitol, and maltitol.
  • the preferred humectants are butylene glycol and glycerin.
  • emollients include, for example, cyclopentasiloxane, dimethicone, ethylhexyl palmitate, polyethylene glycol, polypropylene glycol, silica dimethyl silylate, animal and vegetable fats and oils, myristyl alcohol, alum, glycereth-26, and aluminium acetate, isopropyl palmitate, silicone oils, stearic acid, and stearyl alcohol.
  • the preferred emollients are ethylhexyl palmitate, dimethicone, silica dimethyl silylate, cyclopentasiloxane, polyethylene glycol, and polypropylene glycol.
  • moisturizing agents include, for example, glycerin, sorbitol, polyethylene glycols, polyethylene glycol ethers, urea, and propylene glycol.
  • the preferred moisturizing agent is methyl gluceth-10 (a polyethylene glycol ether of methyl glucose).
  • buffers include, for example, sodium hydroxide, acetate buffers, citrate buffers, phosphate buffers, lactic acid buffers, and borate buffers.
  • the preferred buffer is sodium hydroxide.
  • viscosity controlling agents include, for example, acrylates such as sodium polyacrylate and C10-C30 alkyl acrylate crosspolymer.
  • emulsifiers include, for example, polyethylene glycol ethers (e.g. polyethylene glycol ether of tridecyl alcohol) cetearyl alcohol, glyceryl stearate, sodium stearoyl lactylate, and sorbitan olivate.
  • gelling agents include those known to those skilled in the art, such as hydrophilic and hydroalcoholic gelling agents frequently used in the cosmetic and pharmaceutical industries
  • demulcents include, for example, benzoin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, and polyvinyl alcohol.
  • antioxidants include, for example, ascorbic acid and its esters, sodium bisulfite, butylated hydroxytoluene, butylated hydroxyanisole, tocopherols, and chelating agents like EDTA and citric acid.
  • solubilizing agents include, for example, quaternary ammonium chlorides, cyclodextrins, benzyl benzoate, lecithin, and polysorbates.
  • Examples of skin-penetrating agents include, for example, ethyl alcohol, isopropyl alcohol, octylphenylpolyethylene glycol, oleic acid, polyethylene glycol 400, propylene glycol, N-decylmethylsulfoxide, fatty acid esters (e.g., isopropyl myristate, methyl laurate, glycerol monooleate, and propylene glycol monooleate); and N-methylpyrrolidone.
  • fatty acid esters e.g., isopropyl myristate, methyl laurate, glycerol monooleate, and propylene glycol monooleate
  • N-methylpyrrolidone ethyl alcohol, isopropyl alcohol, octylphenylpolyethylene glycol, oleic acid, polyethylene glycol 400, propylene glycol, N-decylmethylsulfoxide, fatty acid esters
  • surfactants include, for example, carboxylic acid such as stearic acid, sulphates such as sodium lauryl sulphate, ammonium lauryl sulphate, and sodium laureth sulphate, sulphonic acid surfactants such as taurates, isethionates, olefin sulphonates and sulfosuccinates, quaternarized ammonium compounds, alkyimidazolines, alkoxylated amines, sodium lauriminodipropionate, disodium lauroamphodiacetate, alcohols such as cetyl or stearyl alcohol, alkanolamides, esters, and amine oxides.
  • carboxylic acid such as stearic acid
  • sulphates such as sodium lauryl sulphate, ammonium lauryl sulphate, and sodium laureth sulphate
  • sulphonic acid surfactants such as taurates, isethionates, olefin
  • suspending agents include, for example, alginates, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, acacia, tragacanth, xanthan gum, bentonite, carbomer, carrageenan, and gelatin.
  • the sexual pleasure enhancement compositions described herein may further comprise one or more (e.g. all) of water, denatured alcohol, benzyl alcohol, butylene glycol, cyclopentasiloxane, dehydroacetic acid, dimethicone, ethylhexyl palmitate, glycerin, meth gluceth-10 (a polyethylene glycol ether of methyl glucose), polyethylene glycol/polypropylene glycol-18/18 dimethicone, pentylene glycol, silica dimethyl silylate, sodium hyaluronate, sodium hydroxide, sodium polyacrylate, alkyl acrylate crosspolymer, and trideceth-6 (polyethylene glycol ether of tridecyl alcohol).
  • water denatured alcohol
  • benzyl alcohol butylene glycol
  • cyclopentasiloxane dehydroacetic acid
  • dimethicone dimethicone
  • ethylhexyl palmitate
  • the sexual pleasure enhancement composition may, for example, comprise equal to or greater than about 90.0 wt% of ingredients other than the aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may comprise equal to or greater than about 91.0 wt% or equal to or greater than about 92.0 wt% or equal to or greater than about 93.0 wt% or equal to or greater than about 94.0 wt% or equal to or greater than about 95.0 wt% or equal to or greater than about 96.0 wt% of ingredients other than the aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may, for example, comprise equal to or less than about 99.99 wt% of ingredients other than the aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may comprise equal to or less than about 99.97 wt% or equal to or less than about 99.9 wt% or equal to or less than about 99.5 wt% or equal to or less than about 99.0 wt% or equal to or less than about 98.5 wt% or equal to or less than about 98.0 wt% or equal to or less than about 97.5 wt% or equal to or less than about 97.0 wt% of ingredients other than the aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may comprise from about 90.0 wt% to about 99.99 wt% of ingredients other than the aliphatic fluorocarbon compound(s).
  • the sexual pleasure enhancement composition may comprise from about 90.0 wt% to about 99.97 wt% or from about 95.0 wt% to about 99.9 wt% or from about 97.0 wt% to about 99.0 wt% of ingredients other than the aliphatic fluorocarbon co pound(s).
  • the sexual pleasure enhancement composition may, for example, comprise one or more (e.g. all) of the following ingredients with the maximum and/or minimum amounts specified below.
  • the sexual pleasure enhancement composition may, for example, be a gel, an emulsion such as a cream or lotion, a microemulsion, an ointment, an aqueous solution, an aqueous suspension, a foam, a spray, or a salve.
  • the sexual pleasure enhancement compositions described herein are suitable for enhancing sexual pleasure in a subject.
  • the sexual pleasure enhancement compositions described herein may, for example, be used non-therapeutically to enhance sexual pleasure in a subject experiencing normal sexual activity.
  • the sexual pleasure enhancement compositions described herein may be used therapeutically to enhance sexual pleasure in a subject suffering from and/or diagnosed with a sexual dysfunction.
  • therapeutic and non-therapeutic uses of the sexual pleasure enhancement composition described herein are further provided herein.
  • a sexual pleasure enhancement composition as described herein (according to any aspect or embodiment of the present invention) for enhancing sexual pleasure in a subject.
  • a non-therapeutic method for enhancing sexual pleasure in a subject comprising applying a sexual pleasure enhancement composition as described herein (according to any aspect or embodiment of the present invention) to an erogenous zone, such as the genitals and/or the breasts, of the subject.
  • a sexual pleasure enhancement composition as described herein for use in a therapeutic method of treating sexual dysfunction in a subject.
  • a therapeutic method for treating sexual dysfunction in a subject comprising applying a sexual pleasure enhancement composition as described herein (according to any aspect or embodiment of the present invention) to an erogenous zone, such as the genitals and/or the breasts, of the subject.
  • the subject of the uses and methods described herein may, for example, be a human subject.
  • the subject may, for example, be a male or female subject.
  • the subject may, for example, be a male or female human subject.
  • the term“enhancing sexual pleasure in a subject” refers to any increase in enjoyment of sexual activity by the subject. This may, for example, include one or more of increasing sensitivity of an erogenous zone, such as the genitals and/or breasts, of the subject, increasing sexual desire, more pleasurable orgasm, more satisfying orgasm, deeper orgasm, increase in vaginal lubrication, decreased time to arousal, decreased time to orgasm, quicker to obtain erection, longer maintenance of erection, and harder erection.
  • an erogenous zone such as the genitals and/or breasts
  • the female sexual response has been divided into four phases:
  • Excitement - consisting of subjective senses of sexual enjoyment and accompanying physiological changes including vasocongestion in the pelvis, vaginal lubrication, and expansion and swelling of the external genetalia;
  • the sexual pleasure enhancement compositions may be used to enhance any of these four phrases in a female subject.
  • the male sexual response relates to the ability to cause and sustain an erection.
  • the sexual pleasure enhancement compositions may be used to enhance the ability to cause and/or sustain an erection in a male subject.
  • treating and analogous terms used herein refers to all forms of healthcare intended to remove or avoid the disease or to relieve its symptoms, including preventive and curative care, as judged according to any of the tests available according to the prevailing medical practice. An intervention that aims with reasonable expectation to achieve a particular result but does not always do so is included within the term“treating”. Enhancing sexual pleasure in a subject having a sexual dysfunction is encompassed within“treating sexual dysfunction” in that subject.
  • sexual dysfunction refers to difficulty experienced by an individual during any stage of normal sexual activity, including physical pleasure, desire, preference, arousal, or orgasm. Sexual dysfunction may be diagnosed in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), which requires a person to feel extreme distress and interpersonal strain for a minimum of six months (excluding substance or medication-induced sexual dysfunction).
  • DSM-5 Diagnostic and Statistical Manual of Mental Disorders
  • Sexual dysfunction includes, for example, hypoactive sexual desire disorders, sexual arousal disorders, erectile dysfunction, premature ejaculation, orgasm disorders, and sexual pain disorders. These dysfunctions may, for example, be diagnosed in accordance with DSM-5.
  • the sexual dysfunction to be treated by the compositions described herein may, for example, be hypoactive sexual desire disorder, which is characterized by a lack or absence of desire for sexual activity. This may, for example, be diagnosed in accordance with DSM-5.
  • the sexual pleasure enhancement compositions described herein may, for example, be applied to the genitals and/or the breasts of the subject.
  • the compositions may be applied to the mons pubis, anterium, labium posterius, labia, outer area of the vagina, clitoris or the clitoral hood.
  • the sexual pleasure enhancement compositions may be applied to the clitoris or the clitoral hood.
  • the sexual pleasure enhancement compositions may be applied to the penal hood.
  • the sexual pleasure enhancement compositions may be applied to the areola of the breasts of a male or female subject.
  • the sexual pleasure enhancement compositions described herein may, for example, be applied in any suitable amount to obtain an enhancement in sexual pleasure.
  • the sexual pleasure enhancement compositions described herein may be applied in an amount ranging from about 0.1 g/cm 2 to about 10 g/cm 2 or from about 0.5 g/cm 2 to about 5 g/cm 2 or from about 1.0 g/cm 2 to about 3 g/cm 2 , based on the surface area of skin that it is applied to.
  • the sexual pleasure enhancement compositions described herein may, for example, be applied up to 20 minutes before sexual activity, for example up to 20 minutes before sexual intercourse.
  • the sexual pleasure enhancement compositions described herein may be applied up to 15 minutes before or up to 10 minutes before or up to 5 minutes before sexual activity, for example before sexual intercourse.
  • the sexual pleasure enhancement compositions described herein may, for example, be applied during sexual activity.
  • the sexual pleasure enhancement compositions described herein may, for example, be applied once prior to or during sexual activity.
  • the sexual pleasure enhancement compositions described herein may be applied 2 or more times prior to and/or during sexual activity.
  • the sexual pleasure enhancement compositions described herein may be applied up to 10 times prior to and/or during sexual activity.
  • compositions described herein comprising mixing the aliphatic fluorocarbon compound(s) with any other components of the composition.
  • the components may be mixed using any suitable mixing equipment.
  • the mixing may, for example, include high shear mixing.
  • the components may be mixed in any suitable order.
  • the aliphatic fluorocarbon compound(s) may, for example, be mixed with other components of the composition after the other components of the composition have been mixed together.
  • the aliphatic fluorocarbon compound(s) may be added directly to an emulsion after emulsification.
  • components present in a water-phase may, for example be mixed together and components present in an oil-phase may be mixed together.
  • the water-phase components may then be mixed with the oil-phase components to form an emulsion.
  • the aliphatic fluorocarbon compound(s) may then be mixed with the emulsion.
  • the sexual pleasure enhancement composition may, for example, be made at a relatively low temperature, for example at a temperature equal to or less than about 35°C.
  • the composition may be made at a temperature equal to or less than about 30°C or equal to or less than about 25°C or equal to or less than about 20°C or equal to or less than about 15°C or equal to or less than about 10°C.
  • the sexual pleasure enhancement composition may be made at a temperature equal to or greater than about 0°C or equal to or greater than about 2°C or equal to or greater than about 5°C. Manufacturing the sexual pleasure enhancement composition at temperatures equal to or less than about 35°C, particularly temperatures equal to or less than about 10°C, may assist in preventing evaporation and bubbling of the composition.
  • the sexual pleasure enhancement composition may, for example, be made under vacuum. Manufacturing the sexual pleasure enhancement composition under vacuum may assist in preventing evaporation and bubbling of the composition.
  • oxygen may be bubbled through aliphatic fluorocarbon compound(s) before they are mixed with the other components of the composition.
  • any additional oxygen may be bubbled through the sexual pleasure enhancement composition after all the other components of the composition have been mixed.
  • the sexual pleasure enhancement composition may, for example, then be packaged, for example in airless and airtight packaging, to prevent oxygen from diffusing out of the composition.
  • composition shown in Table 1 was made by mixing the components as follows.
  • Hyaluronic Filling SpheresTM are available from BASF and include the following components: ethylhexyl palmitate, silica dimethyl silylate, butylene glycol, pentylene glycol, sodium hyaluronate microparticles, caprylyl glycol, hexylene glycol and phenoxyethanol.
  • composition was provided to 45 women and 15 men who did not have a sexual dysfunction.
  • the women were instructed to apply one pump (approximately 0.75 ml) of the composition to either to the clitoris, clitoral hood area, and clitoral surrounding skin or to the areola.
  • the men were instructed to apply one pump (approximately 0.75 ml) of the composition either to the penal hood or to the areola.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions d'amélioration du plaisir sexuel pour améliorer le plaisir sexuel chez un sujet et les diverses utilisations thérapeutiques et non thérapeutiques des compositions d'amélioration du plaisir sexuel pour améliorer le plaisir sexuel chez un sujet.
PCT/GB2020/051661 2019-07-12 2020-07-10 Compositions d'amélioration du plaisir sexuel WO2021009487A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1910028.8A GB201910028D0 (en) 2019-07-12 2019-07-12 Sexual pleasure enhancement compositions
GB1910028.8 2019-07-12

Publications (1)

Publication Number Publication Date
WO2021009487A1 true WO2021009487A1 (fr) 2021-01-21

Family

ID=67700170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2020/051661 WO2021009487A1 (fr) 2019-07-12 2020-07-10 Compositions d'amélioration du plaisir sexuel

Country Status (2)

Country Link
GB (1) GB201910028D0 (fr)
WO (1) WO2021009487A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562924A (en) 1992-03-11 1996-10-08 Coletica Polysaccharide wall microcapsules containing primary alcohol functions and compositions containing same
RU2082389C1 (ru) * 1994-05-18 1997-06-27 Акционерное общество закрытого типа "Низар" Крем интимного назначения для мужчин
RU2082388C1 (ru) * 1994-05-18 1997-06-27 Акционерное общество закрытого типа "Низар" Крем интимного назначения для женщин
US20100144861A1 (en) * 2008-11-25 2010-06-10 Gary Huvard Perfluorocarbon gel formulations
US20100267842A1 (en) * 2009-04-15 2010-10-21 Richard Kiral Emulsions of Perfluorocarbons
US20120225102A1 (en) * 2008-11-25 2012-09-06 Oxygen Biotherapeutics, Inc. Perfluorocarbon gel formulations
US20130059021A1 (en) * 2011-02-16 2013-03-07 Oxygen Biotherapeutics, Inc. Perfluoro(n-butylcyclohexane) compositions and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562924A (en) 1992-03-11 1996-10-08 Coletica Polysaccharide wall microcapsules containing primary alcohol functions and compositions containing same
RU2082389C1 (ru) * 1994-05-18 1997-06-27 Акционерное общество закрытого типа "Низар" Крем интимного назначения для мужчин
RU2082388C1 (ru) * 1994-05-18 1997-06-27 Акционерное общество закрытого типа "Низар" Крем интимного назначения для женщин
US20100144861A1 (en) * 2008-11-25 2010-06-10 Gary Huvard Perfluorocarbon gel formulations
US20120225102A1 (en) * 2008-11-25 2012-09-06 Oxygen Biotherapeutics, Inc. Perfluorocarbon gel formulations
US20100267842A1 (en) * 2009-04-15 2010-10-21 Richard Kiral Emulsions of Perfluorocarbons
US20130059021A1 (en) * 2011-02-16 2013-03-07 Oxygen Biotherapeutics, Inc. Perfluoro(n-butylcyclohexane) compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"The Science and Practice of Pharmacy, Mack Publishing Company", 1995

Also Published As

Publication number Publication date
GB201910028D0 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
AU2018347514B2 (en) Methods and compositions for topical delivery
US5002974A (en) Anesthetic/skin moisturizing composition and method of preparing same
KR20190101948A (ko) 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
KR19980702766A (ko) 니트로글리세린을 함유하는 수용성기제의 외용크림; 그 제조방법 및 용도
TW201242618A (en) Pharmaceutical cream compositions and methods of use
JP2009184951A (ja) 皮膚外用剤組成物
CN104434768A (zh) 一种具有缓释功效的保湿化妆水及其制备方法
CN105434337B (zh) 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途
CA2685321A1 (fr) Systeme d'administration solubilisee pour anesthesiques topiques
KR20230151061A (ko) 연성 항콜린제 유사체를 위한 제제
JP2019513820A (ja) タクロリムスを含む局所組成物
WO1999038472A2 (fr) Composition de gel de vasodilatation topique et ses methodes d'utilisation et de production
JP6993987B2 (ja) 慢性の外陰部および会陰部の痛みならびにそれに関連する症状および状態の処置のための組成物
WO2013190542A2 (fr) Compositions topiques pour le traitement de maladies inflammatoires chroniques de la peau
WO2021009487A1 (fr) Compositions d'amélioration du plaisir sexuel
JP2022501345A (ja) 脂質バリアの修復
CN108366991A (zh) 用于治疗和/或预防粘膜的干燥和刺激的吡咯烷酮羧酸和/或其盐与透明质酸和/或其盐的协同配混物、及相关的药物制剂
JP4098799B2 (ja) アスコルビン酸誘導体およびポリアミド粒子を含む組成物の美容使用
JP4157889B2 (ja) 性交機能改善用外用製剤
PT2011504E (pt) Agente dermatológico para o tratamento e/ou de cuidados da pele nos casos de dermatite atópica
US20210024636A1 (en) Compositions and methods for treating sexual dysfunction
JP6689298B2 (ja) ケラチン及び硫黄を含有する局所適用の減量化粧品組成物
WO2012071480A2 (fr) Formulations monothérapeutiques de glucocorticostéroïdes lipophiles et procédés pour le traitement cosmétique de l'adiposité et du bombement de la silhouette
JPH08165244A (ja) 皮膚疾患治療剤
Zhou Clinical Application of Two Allergy-Relieving Formulas Replacing Topical Glucocorticosteroids in the Treatment of Cosmetic Dermatitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20742395

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20742395

Country of ref document: EP

Kind code of ref document: A1